| Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis S Moran, A Martínez-Cardús, S Sayols, E Musulén, C Balañá, ... The Lancet Oncology 17 (10), 1386-1395, 2016 | 436 | 2016 |
| Tumor-related molecular mechanisms of oxaliplatin resistance E Martinez-Balibrea, A Martínez-Cardús, A Ginés, V Ruiz de Porras, ... Molecular cancer therapeutics 14 (8), 1767-1776, 2015 | 292 | 2015 |
| Resistant mechanisms to BRAF inhibitors in melanoma JL Manzano, L Layos, C Bugés, M de los Llanos Gil, L Vila, ... Annals of translational medicine 4 (12), 2016 | 275 | 2016 |
| Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer H Heyn, E Vidal, HJ Ferreira, M Vizoso, S Sayols, A Gomez, S Moran, ... Genome biology 17, 1-16, 2016 | 210 | 2016 |
| Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ... The Lancet Respiratory Medicine 6 (10), 771-781, 2018 | 184 | 2018 |
| Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer A Diaz-Lagares, AB Crujeiras, P Lopez-Serra, M Soler, F Setien, A Goyal, ... Proceedings of the National Academy of Sciences 113 (47), E7535-E7544, 2016 | 159 | 2016 |
| Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs V Nogales, WC Reinhold, S Varma, A Martinez-Cardus, C Moutinho, ... Oncotarget 7 (3), 3084, 2016 | 137 | 2016 |
| UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy E Martinez-Balibrea, A Abad, A Martínez-Cardús, A Ginés, M Valladares, ... British journal of cancer 103 (4), 581-589, 2010 | 130 | 2010 |
| Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program M Janin, V Ortiz-Barahona, MC de Moura, A Martínez-Cardús, ... Acta neuropathologica 138, 1053-1074, 2019 | 123 | 2019 |
| Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway V Ruiz de Porras, S Bystrup, A Martínez-Cardús, R Pluvinet, L Sumoy, ... Scientific reports 6 (1), 24675, 2016 | 123 | 2016 |
| Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR M Vizoso, HJ Ferreira, P Lopez-Serra, FJ Carmona, A Martínez-Cardús, ... Nature medicine 21 (7), 741-750, 2015 | 119 | 2015 |
| Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer C Moutinho, A Martinez-Cardús, C Santos, V Navarro-Pérez, ... Journal of the national cancer institute 106 (1), djt322, 2014 | 108 | 2014 |
| A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect P Lopez-Serra, M Marcilla, A Villanueva, A Ramos-Fernandez, A Palau, ... Nature communications 5 (1), 3608, 2014 | 106 | 2014 |
| Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary S Moran, A Martinez-Cardús, S Boussios, M Esteller Nature reviews Clinical oncology 14 (11), 682-694, 2017 | 99 | 2017 |
| Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer E Martinez-Balibrea, A Abad, E Aranda, J Sastre, JL Manzano, ... European Journal of Cancer 44 (9), 1229-1237, 2008 | 97 | 2008 |
| Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis C Anadón, S Guil, L Simó-Riudalbas, C Moutinho, F Setien, ... Oncogene 35 (33), 4407-4413, 2016 | 89 | 2016 |
| Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells C Plasencia, E Martinez-Balibrea, A Martinez-Cardus, DI Quinn, A Abad, ... International journal of oncology 29 (1), 225-235, 2006 | 86 | 2006 |
| A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines E Martinez-Balibrea, C Plasencia, A Ginés, A Martinez-Cardús, ... Molecular cancer therapeutics 8 (4), 771-778, 2009 | 83 | 2009 |
| KAT6B is a tumor suppressor histone H3 lysine 23 acetyltransferase undergoing genomic loss in small cell lung cancer L Simó-Riudalbas, M Pérez-Salvia, F Setien, A Villanueva, C Moutinho, ... Cancer research 75 (18), 3936-3945, 2015 | 80 | 2015 |
| Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy E Martinez‐Balibrea, A Martínez‐Cardús, E Musulén, A Ginés, ... International journal of cancer 124 (12), 2905-2910, 2009 | 80 | 2009 |
